Cargando…

Conquering Cancer Multi-Drug Resistance Using Curcumin and Cisplatin Prodrug-Encapsulated Mesoporous Silica Nanoparticles for Synergistic Chemo- and Photodynamic Therapies

Recently, the development of anti-cancer approaches using different physical or chemical pathways has shifted from monotherapy to synergistic therapy, which can enhance therapeutic effects. As a result, enormous efforts have been devoted to developing various delivery systems encapsulated with dual...

Descripción completa

Detalles Bibliográficos
Autores principales: Busa, Prabhakar, Kankala, Ranjith Kumar, Deng, Jin-Pei, Liu, Chen-Lun, Lee, Chia-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609490/
https://www.ncbi.nlm.nih.gov/pubmed/36296885
http://dx.doi.org/10.3390/nano12203693
_version_ 1784819032793284608
author Busa, Prabhakar
Kankala, Ranjith Kumar
Deng, Jin-Pei
Liu, Chen-Lun
Lee, Chia-Hung
author_facet Busa, Prabhakar
Kankala, Ranjith Kumar
Deng, Jin-Pei
Liu, Chen-Lun
Lee, Chia-Hung
author_sort Busa, Prabhakar
collection PubMed
description Recently, the development of anti-cancer approaches using different physical or chemical pathways has shifted from monotherapy to synergistic therapy, which can enhance therapeutic effects. As a result, enormous efforts have been devoted to developing various delivery systems encapsulated with dual agents for synergistic effects and to combat cancer cells acquired drug resistance. In this study, we show how to make Institute of Bioengineering and Nanotechnology (IBN)-1-based mesoporous silica nanoparticles (MSNs) for multifunctional drug delivery to overcome drug resistance cancer therapy. Initially, curcumin (Cur)-embedded IBN-1 nanocomposites (IBN-1-Cur) are synthesized in a simple one-pot co-condensation and then immobilized with the prodrug of Cisplatin (CP) on the carboxylate-modified surface (IBN-1-Cur-CP) to achieve photodynamic therapy (PDT) and chemotherapy in one platform, respectively, in the fight against multidrug resistance (MDR) of MES-SA/DX5 cancer cells. The Pluronic F127 triblock copolymer, as the structure-directing agent, in nanoparticles acts as a p-glycoprotein (p-gp) inhibitor. These designed hybrid nanocomposites with excellent structural properties are efficiently internalized by the endocytosis and successfully deliver Cur and CP molecules into the cytosol. Furthermore, the presence of Cur photosensitizer in the nanochannels of MSNs resulted in increased levels of cellular reactive oxygen species (ROS) under light irradiation. Thus, IBN-1-Cur-CP showed excellent anti-cancer therapy in the face of MES-SA/DX5 resistance cancer cells, owing to the synergistic effects of chemo- and photodynamic treatment.
format Online
Article
Text
id pubmed-9609490
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96094902022-10-28 Conquering Cancer Multi-Drug Resistance Using Curcumin and Cisplatin Prodrug-Encapsulated Mesoporous Silica Nanoparticles for Synergistic Chemo- and Photodynamic Therapies Busa, Prabhakar Kankala, Ranjith Kumar Deng, Jin-Pei Liu, Chen-Lun Lee, Chia-Hung Nanomaterials (Basel) Article Recently, the development of anti-cancer approaches using different physical or chemical pathways has shifted from monotherapy to synergistic therapy, which can enhance therapeutic effects. As a result, enormous efforts have been devoted to developing various delivery systems encapsulated with dual agents for synergistic effects and to combat cancer cells acquired drug resistance. In this study, we show how to make Institute of Bioengineering and Nanotechnology (IBN)-1-based mesoporous silica nanoparticles (MSNs) for multifunctional drug delivery to overcome drug resistance cancer therapy. Initially, curcumin (Cur)-embedded IBN-1 nanocomposites (IBN-1-Cur) are synthesized in a simple one-pot co-condensation and then immobilized with the prodrug of Cisplatin (CP) on the carboxylate-modified surface (IBN-1-Cur-CP) to achieve photodynamic therapy (PDT) and chemotherapy in one platform, respectively, in the fight against multidrug resistance (MDR) of MES-SA/DX5 cancer cells. The Pluronic F127 triblock copolymer, as the structure-directing agent, in nanoparticles acts as a p-glycoprotein (p-gp) inhibitor. These designed hybrid nanocomposites with excellent structural properties are efficiently internalized by the endocytosis and successfully deliver Cur and CP molecules into the cytosol. Furthermore, the presence of Cur photosensitizer in the nanochannels of MSNs resulted in increased levels of cellular reactive oxygen species (ROS) under light irradiation. Thus, IBN-1-Cur-CP showed excellent anti-cancer therapy in the face of MES-SA/DX5 resistance cancer cells, owing to the synergistic effects of chemo- and photodynamic treatment. MDPI 2022-10-21 /pmc/articles/PMC9609490/ /pubmed/36296885 http://dx.doi.org/10.3390/nano12203693 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Busa, Prabhakar
Kankala, Ranjith Kumar
Deng, Jin-Pei
Liu, Chen-Lun
Lee, Chia-Hung
Conquering Cancer Multi-Drug Resistance Using Curcumin and Cisplatin Prodrug-Encapsulated Mesoporous Silica Nanoparticles for Synergistic Chemo- and Photodynamic Therapies
title Conquering Cancer Multi-Drug Resistance Using Curcumin and Cisplatin Prodrug-Encapsulated Mesoporous Silica Nanoparticles for Synergistic Chemo- and Photodynamic Therapies
title_full Conquering Cancer Multi-Drug Resistance Using Curcumin and Cisplatin Prodrug-Encapsulated Mesoporous Silica Nanoparticles for Synergistic Chemo- and Photodynamic Therapies
title_fullStr Conquering Cancer Multi-Drug Resistance Using Curcumin and Cisplatin Prodrug-Encapsulated Mesoporous Silica Nanoparticles for Synergistic Chemo- and Photodynamic Therapies
title_full_unstemmed Conquering Cancer Multi-Drug Resistance Using Curcumin and Cisplatin Prodrug-Encapsulated Mesoporous Silica Nanoparticles for Synergistic Chemo- and Photodynamic Therapies
title_short Conquering Cancer Multi-Drug Resistance Using Curcumin and Cisplatin Prodrug-Encapsulated Mesoporous Silica Nanoparticles for Synergistic Chemo- and Photodynamic Therapies
title_sort conquering cancer multi-drug resistance using curcumin and cisplatin prodrug-encapsulated mesoporous silica nanoparticles for synergistic chemo- and photodynamic therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609490/
https://www.ncbi.nlm.nih.gov/pubmed/36296885
http://dx.doi.org/10.3390/nano12203693
work_keys_str_mv AT busaprabhakar conqueringcancermultidrugresistanceusingcurcuminandcisplatinprodrugencapsulatedmesoporoussilicananoparticlesforsynergisticchemoandphotodynamictherapies
AT kankalaranjithkumar conqueringcancermultidrugresistanceusingcurcuminandcisplatinprodrugencapsulatedmesoporoussilicananoparticlesforsynergisticchemoandphotodynamictherapies
AT dengjinpei conqueringcancermultidrugresistanceusingcurcuminandcisplatinprodrugencapsulatedmesoporoussilicananoparticlesforsynergisticchemoandphotodynamictherapies
AT liuchenlun conqueringcancermultidrugresistanceusingcurcuminandcisplatinprodrugencapsulatedmesoporoussilicananoparticlesforsynergisticchemoandphotodynamictherapies
AT leechiahung conqueringcancermultidrugresistanceusingcurcuminandcisplatinprodrugencapsulatedmesoporoussilicananoparticlesforsynergisticchemoandphotodynamictherapies